

Docket No. D0029np
M&F, LLP Ref. No. 3035-4113US1
Express Mail No. EL 912 003 539 US



23914

PATENT TRADEMARK OFFICE

↑AFFIX CUSTOMER NO. LABEL ABOVE ↑

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

UTILITY APPLICATION AND FEE TRANSMITTAL §(1.53(b))

Commissioner for Patents
BOX: PATENT APPLICATION
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s) names and addresses:

- (1) Juan J. PEREZ-VILLAR
11 Carrousel Lane
Mercerville, NJ 08619 USA
- (2) Han CHANG
2 Ann's Court
Princeton Junction, NJ 08550 USA
- (3) Wen-Pin YANG
245 Rutgers Lane
Princeton, NJ 08540 USA
- (4) Yuli WU
3 Susanna Way
Newtown, PA 18940 USA
- (5) Gena S. WHITNEY
72 Hopatcong Drive
Lawrenceville, NJ 08648 USA
- (6) Steven B. KANNER
16 Honey Brook Drive
Princeton, NJ 08540 USA

Additional inventors are listed on a separate sheet

jc821 U.S. PTO
09/966955
09/26/01



For: **Identification and Cloning of a Full-length Human Clnk-related Gene, MIST
(Mast Cell Immunoreceptor Signal Transducer)**

Enclosed Are:

129 total pages of Application, including:

118 page(s) of Specification

1 page(s) of Abstract

10 page(s) of Claims

21 sheets of Formal Informal drawings

 page(s) of Declaration and Power of Attorney

Unsigned

Newly Executed

Copy from prior application

Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)

REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/35)

As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).

Incorporation by Reference:

The entire disclosure of the prior application, from which a copy of the combined Declaration and Power of Attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.

Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b))

Signed statement attached deleting inventor(s) named in the prior application serial no. , filed .

Microfiche Computer Program (Appendix)

20 Page(s) of Sequence Listing

Computer readable disk containing Sequence Listing

Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same

Assignment Papers (assignment cover sheet and assignment documents)

A check in the amount of \$40.00 for recording the Assignment

Charge the Assignment Recordation Fee to Deposit Account No. 13-4500, Order No. .

Assignment Papers filed in the parent application Serial No.

Certification of chain of title pursuant to 37 C.F.R. §3.73(b)

Priority is claimed under 35 U.S.C. §119 for:
Application No(s). _____, filed _____, in _____ (country).

Certified Copy of Priority Document(s) [_____]
 filed herewith
 filed in application Serial No. _____, filed _____.

English translation document(s) [_____]
 filed herewith
 filed in application Serial No. _____, filed _____.

Priority is claimed under 35 U.S.C. §119(e) for:
Provisional Application No. 60/237,030, filed September 29, 2000.

Information Disclosure Statement
 Copy of [_____] cited references
 PTO Form-1449
 References cited in parent application Serial No. _____, filed _____.

Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)
 A copy of related pending U.S. Application(s) Serial No(s): _____, filed _____, respectively, is attached hereto.
 A copy of related pending U.S. Application(s) entitled, _____, filed _____ to inventor(s) _____, respectively, is attached hereto.
 A copy of each related application(s) was submitted in parent application serial no. _____, filed _____.

Preliminary Amendment

Return receipt postcard (MPEP 503)

This is a continuation divisional continuation-in-part of prior application serial no. _____, filed _____, to which priority under 35 U.S.C. §120 is claimed.
 Cancel in this application original claims _____ of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
 A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).

The status of the parent application is as follows:
 A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until _____.
 A copy of the Petition for Extension of Time in the co-pending parent application is attached.

No Petition for Extension of Time and Fee therefor are necessary in the co-pending parent application.

Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.

Transfer the drawing(s) from the parent application to this application

Amend the specification by inserting before the first line the sentence:
This is a continuation divisional continuation-in-part of co-pending application Serial No. _____, filed _____.

I. CALCULATION OF APPLICATION FEE				
	Number Filed	Number Extra	Rate	Basic Fee \$710.00/355.00
Total Claims	40- 20 =	20x	\$18.00/ \$9.00	\$ 360.00
Independent Claims	6- 3 =	3x	\$80.00/ \$40.00	\$ 240.00
<input checked="" type="checkbox"/> Multiple Dependent Claims		If marked, add fee of \$270.00 (\$135.00)		\$ 270.00
				TOTAL: \$ 1580.00

Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith
\$_____.

A check in the amount of \$1580.00 in payment of the application filing fees is attached.

Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, **including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency** with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3053-4113US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

- No Petition for Extension of Time and Fee therefor are necessary in the co-pending parent application.
- Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.
- Transfer the drawing(s) from the parent application to this application
- Amend the specification by inserting before the first line the sentence:
This is a continuation divisional continuation-in-part of co-pending application Serial No. _____, filed _____.

I. CALCULATION OF APPLICATION FEE				
	Number Filed	Number Extra	Rate	Basic Fee
Total Claims	40- 20 =	20x	\$18.00/ \$9.00	\$ 360.00
Independent Claims	6- 3 =	3x	\$80.00/ \$40.00	\$ 240.00
<input checked="" type="checkbox"/> Multiple Dependent Claims	If marked, add fee of \$270.00 (\$135.00)			\$ 270.00
			TOTAL:	\$ 1580.00

- Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith
\$_____.
- A check in the amount of \$1580.00 in payment of the application filing fees is attached.
- Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, **including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency** with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3053-4113US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: September 28, 2001

By:

Leslie Serunian
Leslie A. Serunian
Registration No. 35,353

Correspondence Address:

Bristol-Myers Squibb Company
Route 206 and Provinceline Road
Mail Stop D33-05
Princeton, New Jersey 08540
(609) 252-3953 Telephone
(609) 252-4256 Facsimile

Sender's Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053

(212) 758-4800 Telephone
(212) 751-6849 Facsimile

09/28/01
JCS66 US PTO

10-01-01

Boxseg
A

M&F, LLP Ref. No: 3053-4113US1

BMS Docket No. D0029np

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Juan J. PEREZ-VILLAR et al.

Group Art Unit: To Be Assigned

Serial No.: To Be Assigned

Examiner: To Be Assigned

Filed: September 28, 2001 (Herewith)

For: *Identification and Cloning of a Full-length Human Clnk-related Gene, MIST (Mast Cell Immunoreceptor Signal Transducer)*

JCS66 US PTO
09/28/01
JC821 U.S. S. 09/966955

EXPRESS MAIL CERTIFICATE

Express Mail Label No.: **EL 912 003 539 US**

Date of Deposit: **September 28, 2001**


I hereby certify that the following attached paper(s) and/or fee(s)

1. Utility Application and Fee Transmittal (5 pages);
2. Utility Application containing 129 total pages, including 118 pages of Specification, 10 pages of Claims, 1 page of Abstract;
3. 21 sheets of Drawings (Figs.1A/1B-15A/15B);
4. 20 pages of Sequence Listing;
5. 3.5 inch disk containing Sequence Listing in Computer-readable form
6. Statement of Identity pursuant to 37 CFR 1.821(f);
7. Filing Fee (check for \$1580.00)
8. Return Postcard

is/are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to: **BOX: PATENT APPLICATION**, the Commissioner for Patents, Washington, D.C. 20231.

Jesus R. Remedios

(Typed or printed name of person mailing papers(s) and/or fee)



(Signature of person mailing paper(s) and/or fee)

Sender's Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Juan J. PEREZ-VILLAR et al.

Serial No. : To Be Assigned Group Unit: To Be Assigned

Filed : Herewith (September 28, 2001) Examiner: To Be Assigned

For : **Identification and Cloning of a Full-length Human Cink-related Gene, MIST (Mast Cell Immunoreceptor Signal Transducer)**

Commissioner for Patents
Washington, D.C. 20231

Statement Under 37 C.F.R. §1.821(f) or §1.825(b)

Dear Sir:

I hereby certify that:

[X] The paper Sequence Listing submitted herewith and computer readable Sequence Listing attached hereto are identical (37 C.F.R. §1.821(f)).

[] The substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are identical. No new matter is included (37 C.F.R. §1.825(b)).

Respectfully submitted,

MORGAN & FINNEGAN, LLP

Date: September 28, 2001 By: Leslie Serunian
Leslie A. Serunian
Reg. No. 35,353

CORRESPONDENCE ADDRESS:

Bristol-Myers Squibb Company
Route 206 and Provinceline Road
Princeton, New Jersey 08543-4000
Telephone: (609) 252-3953
Facsimile: (609) 252-4526

SENDER'S ADDRESS:

Morgan & Finnegan, LLP
345 Park Avenue
New York, New York 10154-0053
Telephone: (212) 758-4800
Facsimile: (212) 751-6849